ALTO NEUROSCIENCE INC (ANRO)
US02157Q1094 - Common Stock
Alto Neuroscience to Participate in Upcoming Investor Conferences
ANRO Stock Earnings: Alto Neuroscience Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alto Neuroscience (NYSE:ANRO) just reported results for the second quarter of 2...
ANRO Stock Earnings: Alto Neuroscience Beats EPS for Q2 2024
ANRO stock results show that Alto Neuroscience beat analyst estimates for earnings per share the second quarter of 2024.
Alto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Oversold Conditions For Alto Neuroscience (ANRO)
Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive Disorder
Friday 7/12 Insider Buying Report: ANRO, AHH
Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia
Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner
Wake Up! 3 Lesser-Known Stocks Investors Are Sleeping On
Under-the-radar stocks offer incredible chances at massive returns with these shares representing compelling choices for investors.
Alto Neuroscience to Present at the Jefferies Global Healthcare Conference
Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
ANRO Stock Earnings: Alto Neuroscience Misses EPS for Q1 2024
ANRO stock results show that Alto Neuroscience missed analyst estimates for earnings per share the first quarter of 2024.
ANRO Stock Earnings: Alto Neuroscience Misses EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alto Neuroscience (NYSE:ANRO) just reported results for the first quarter of 20...
Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights
Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder
Tuesday 4/2 Insider Buying Report: WLKP, ANRO
Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights
Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors
Alto Neuroscience to Participate in Upcoming Investor Conferences
Stifel, Baird, Jefferies bullish on Alto Neuroscience, cite upcoming data (NYSE:ANRO)
Stifel, Baird and Jefferies have initiated coverage of newly public Alto Neuroscience (ANRO) with buy ratings, citing upcoming data for the company's psychiatri
Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference
Alto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
The biggest pre-market stock movers are starting off the trading week as we check out all of the hottest news for Monday morning!
Alto Neuroscience stock rallies 35% following upsized IPO (NYSE:ANRO)
Shares of psychiatric drug developer Alto Neuroscience (ANRO) soared 35% on Friday following its upsized $128.6M initial public offering. Read more here.
Alto Neuroscience Announces Pricing of Upsized Initial Public Offering
Alto Neurosciences sets terms for proposed $101M IPO (Pending:ANRO)
Psychiatric drug developer Alto Neuroscience (ANRO) has set terms for a proposed $101M initial public offering. In a recent filing, Alto said it is looking to o
Psychiatric drug developer Alto Neuroscience files for $100M IPO (Pending:ANRO)
Alto Neuroscience (ANRO) has filed for a $100M IPO. The psychiatric drug developer plans to list its shares on NYSE under symbol ANRO. Read more here.